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Abstract
OBJECTIVE: To investigate the application of Tradi-
tional Chinese Medicine Injections (TCMIs) for treat-
ment of primary liver cancer (PLC).
METHODS: A literature review was conducted us-
ing PubMed/Medline, Cochrane Library Controlled
Clinical Trials Database, China National Knowledge
Infrastructure (CNKI), China Scientific Journal Data-
base (CSJD) and China Biology Medicine (CBM). On-
line websites including journal websites and data-
bases of ongoing trials, as well as some Traditional
Chinese Medicine journals that are not indexed in
the electronic databases were also searched.
RESULTS: The literature review showed that TCMIs
as adjunctive medication for the treatment of PLC
could regulate patient immunity, reduce bone mar-
row suppression, relieve clinical symptoms, and im-
prove quality of life, as well as control disease pro-
gression and prolong survival time.
CONCLUSION:Within the limitations of this review,
we conclude that application of TCMIs as adjunc-
tive medication may provide benefits for patients
with PLC. Further large, high-quality trials are war-
ranted.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Primary liver cancer (PLC) is the sixth most common
cancer worldwide, and the third most common in Chi-
na.1 In 2005, the incidence of PLC in China was about
345,000, which accounted for >50% of those world-
wide.1 Surgical resection is still the dominant therapy
for PLC, but many patients have lost the opportunity
for surgery by the time their diagnosis has been con-
firmed.2 At the same time, the postoperative recurrence
rate of PLC is high. As the result, multidisciplinary
therapy is essential for PLC patients. In China and
some Southeast Asian countries, Chinese herbal medi-
cine has been used to treat malignant tumors, includ-
ing PLC, for a long time. With the development of
Chinese herbal pharmaceutical technology, more Tradi-
tional Chinese Medicine injections (TCMIs) have been
used for treatment of PLC in China. TCMIs are partic-
ularly preferred for elderly patients or those with ad-
vanced disease.
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It has been revealed that TCMIs have variable effects,
such as activity against tumor angiogenesis, induction
of cancer cell apoptosis, regulation of immunity, and
analgesia.3-6 Therefore, TCMIs are becoming popular
for antineoplastic therapy. In this paper, we give an
overview of the application of TCMIs in PLC.
METHODS
Data sources
A review of the medical literature to March 13, 2011
was conducted using PubMed/Medline, Cochrane Li-
brary Controlled Clinical Trials Database, China Na-
tional Knowledge Infrastructure (CNKI), China Scien-
tific Journal Database (CSJD) and China Biology Med-
icine (CBM). Language was limited to English when
searching PubMed/Medline and the Cochrane Library.
The search terms used were ((primary liver cancer)
AND injection). Searching was conducted to identify
all relevant studies regardless of publication status. We
also searched online websites including journal web-
sites and databases of ongoing trials. In addition, some
TCM journals that were not indexed in the electronic
databases were retrieved, and articles listed in the refer-
ences of our retrieved papers or listed in conference
proceedings were also included.
Inclusion criteria
Articles were included if: 1) all reported cases of PLC
were diagnosed by pathological or imaging data; 2)
they were about clinical trials of TCMIs for treatment
of PLC; 3) TCMIs were used exclusively or in combina-
tion with other therapeutic methods; 4) they were all
read, and data were extracted based on predefined selec-
tion criteria by reviewers– agreement between review-
ers for inclusion of studies was recorded.
RESULTS
Thirty-four papers on TCMI treatment of PLC were
generated from the initial search. Among those TC-
MIs, 12 commonly used ones which high frequency of
use in the literatures were Brucea Javanica oil emulsion
injection, Aidi injection, Cinobufacini injection, arse-
nic trioxide injection, Kang-Lai-Te injection, Xiao'aip-
ing injection, Composite Danshen injection, Compos-
ite Sophorae Flavescentis injection, Kang Ai injection,
Sheng Mai injection, Shen Qi Fu Zheng injection, and
Shen Fu injection. Brief descriptions of the TCMIs
mentioned above are listed in Table 1. The clinical ap-
plication of the TCMIs is outlined below.
Combination with intervention therapy
For combined treatment of PLC with intravenous Bru-
cea Javanica oil emulsion injection and transcatheter ar-
terial chemoembolization (TACE), the partial remis-
sion (PR) and stable disease (SD) rates and Karnofsky
Performance Scale (KPS) score in the treatment group
were higher than those in the control group.7 Com-
bined treatment of mid to late stage PLC by Brucea Ja-
vanica oil emulsion injection and TACE improved
quality of life (QOL) and relieved nausea, vomiting, fe-
ver, thrombocytopenia, aleukocytosis, and renal and he-
patic dysfunction;8 it also relieved nausea, vomiting
and aleukocytosis, improving QOL markedly, especial-
ly for patients aged >50 years.9 You, et al.10 found that
10 patients who underwent percutaneous injection of
Brucea Javanica oil emulsion injection plus ethanol
and B ultrasound therapy all lived for >6 months.
Studies on Aidi injection revealed that the PR and SD
rates and KPS scores in the treatment group were high-
er than those in the control group; furthermore, there
was also a higher negative conversion rate and descend-
ing amplitude of a-fetoprotein (AFP), as well as a high
6-month survival rate.11,12
Daily Cinobufacini injection for 4 weeks improved
bone marrow protection, alleviated clinical symptoms,
and increased peripheral white blood cells (PWBCs),
CD3+ and CD4+ cells, CD4+/CD8+ cell ratio and natu-
ral killer (NK) cells.13,14 At the same time, there was a
significant increase in 6-month survival rate, median
survival time, and 1- and 2-year survival rates.15,16 As to
the antifebrile effect, Intravenous Cinobufacini injec-
tion had a superior antifebrile effect than oral indo-
methacin after TACE.17
Another study showed that intratumoral arsenic triox-
ide injection after TACE increased complete remission
(CR) and PR rates, and 1-, 2- and 3-year survival
rates.18 Applying continuous intravenous pump injec-
tion of arsenic trioxide in combination with TACE im-
proved QOL and 1-year survival rate.19
Kang-Lai-Te injection after TACE increased CR, PR
and no change rates,20 as well as significantly alleviating
the symptoms of hepatalgia, abdominal distension, an-
orexia and fatigue.21 In the Kang-Lai-Te injection
group, the descending amplitude of AFP and 6-month
survival rate were higher than those in the control
group.22
For intravenous Shen Fu injection after TACE, KPS
score was higher,23 and intravenous Shen Qi Fu Zheng
injection significantly increased the number of CD3 +
and CD4+ cells, and the CD4+/CD8+ cells ratio.24
Du Zhiqiang, et al. found that intravenous Cinobufaci-
ni injection and Sheng Mai injection after treatment
with the Cryocare Surgical System significantly in-
creased CD3 + , CD4 + and NK cell levels and CD4 +/
CD8 + cell, and there was no evidence of liver injury,
such as elevated alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), total bilirubin (TBIL),
and reduced albumin (ALB). The recurrence rate of pa-
tients with tumor ≥3 cm was significantly lower than
that in the control group.25
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Clinical observations showed that, in patients treated
concurrently with Cinobufacini or Kang-Lai-Te injec-
tion and radiotherapy, KPS scores were increased, appe-
tite improved, and pain was relieved. Also, the CR and
PR rates were higher when using Kang-Lai-Te injec-
tion.26,27
Combination with radiotherapy
Aidi injection with percutaneous radiofrequency abla-
tion (PRFA) significantly increased the CR and PR
rates and the 12-, 18- and 24-month survival rates. In-
creases in CD3+ and CD4+ cells, CD4+/CD8+ cell ratio
and NK cells, and alleviation of clinical symptoms
such as hepatalgia, fever, abdominal distension, anorex-
ia and jaundice were more evident in the treatment
group, whereas descending amplitudes of AFP, ALT
and AST were the same as in the control group.28-30
Similar effects were seen with Kang Ai injection.31
However, the recurrence rate of the patients with tu-
mors ≥3 cm was significantly lower when PRFA was ap-
plied in combination with those two injections.31, 32
Clinical observations have shown that Shen Qi Fu
Zheng injection in combination with gamma knife ra-
diosurgery increased KPS scores and body weight, but
did not significantly affect PWBC count, hemoglobin,
or platelet and CD4+ cell counts.33
Another study revealed that Xiao'aiping injection re-
duced the duration of fever after PRFA.34
Combination with chemotherapy
When chemotherapeutic drugs such as fluorouracil
(5-FU) or meloxicam were used in combination with
Aidi injection, the reduction in PWBC count and
symptoms such as nausea, vomiting and low fever were
significantly lowered in the treatment group compared
with the control group.35,36 Moreover, in mid to late
stage PLC, 5-FU in combination with Aidi injection
increased the efficacy and 6- and 12-month survival
rates, relieved the clinical symptoms, and reduced the
nausea and aleukocytosis for the patients in the treat-
ment group compared with 5-FU alone, according to
clinical observation.37
The same therapeutic efficacy were achieved when in-
travenous drip of Shengqi Fuzheng injection was com-
bined with cisplatin, adriamycin, 5-FU plus interferon,
as well as when intravenous drip of Cinobufacini injec-
tion was combined with 5-FU and hydroxycamptothe-
cin (HCPT).38,39 When Kang-Lai-Te injection was used
with capecitabine, the total effectiveness, clinical bene-
fit response rate, time-to-progression, and mean surviv-
al time were higher in the treatment group.40
Intravenous drip of Composite Sophorae Flavescentis
injection combined with epirubicin, 5-FU plus cisplat-
in improved the curative effect, 1-year survival rate, cel-
lular immune function, and QOL, and decreased the
reduction in PWBC count, pain, and toxicity of che-
motherapy in patients with advanced PLC.3,41 Another
study showed that intra-abdominal injection with
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HCPT, 5-FU plus dexamethasone in combination
with Composite Sophorae Flavescentis injection in-
creased the efficacy of treating cancerous ascites and re-
duced the side effects of intraperitoneal chemotherapy
compared with intra-abdominal injection with HCPT,
5-FU plus dexamethasone.42 Similar effects could be
seen when applying intra-abdominal injection of dopa-
mine plus furosemide in combination with Composite
Danshen injection.43
Combination with surgery
Li et al. found that compared with operation alone, in-
travenous Shen Fu injection as preoperative adjuvant
therapy increased the levels of CD3+ and CD4+ cells,
protected liver function, shortened the length of stay in
hospital or intensive care unit, and enabled earlier post-
operative decannulation. And scores of KPS could be
increased significantly 30 days after the surgery.44
Another study showed that compared with operation
alone, intravenous Kang-ai injection as preoperative ad-
juvant therapy increased the levels of CD3+ and CD4+
cells and CD4+/CD8+ cell ratio in patients with prima-
ry hepatic carcinoma.45
Monotherapy
Compared with liver-protecting treatment, Cinobufaci-
ni injection in combination with symptomatic treat-
ment inhibited cancer proliferation, and protected liver
function, improved QOL, and prolonged survival
time. ALT and TBIL levels decreased significantly in
patients in the treatment group.46,47
Another study showed that hepatalgia was alleviated by
Composite Sophorae Flavescentis injection.48 Tan
found that compared with ascites drainage alone, in-
tra-abdominal Composite Sophorae Flavescentis injec-
tion after ascites drainage could improve alleviation of
cancerous ascites in PLC.49
In a study that included 25 patients with advanced
PLC treated with intravenous arsenic trioxide injec-
tion, the response rate was 13.8% .50 Compared with
liver-protecting treatment alone, Arsenic trioxide injec-
tion increased the levels of CD3+, CD4+ and CD8+
cells, and CD4+/CD8+ cell ratio, and enhanced KPS
score.51
In patients with late-stage liver cancer, intravenous
Aidi injection could increased daily food consumption
and relieved pain after 2 months of treatment com-
pared with symptomatic therapy,52 and KPS score was
increased significantly in the treatment group.53 Anoth-
er study showed that compared with liver-protecting
treatment, intravenous drip of arsenic trioxide injec-
tion plus Aidi injection also increased the CD3 + ,
CD4+ and CD8+ cells and CD4+/CD8+ cell ratio,
and reduced the level of AFP.54
Wu et al. found that clinical symptoms were alleviated,
KPS scores were increased, and toxicity was reduced in
patients treated with Kang-Lai-Te injection compared
with those in the control group treated with 5-FU plus
oxaliplatin.55
DISCUSSION
Herbs have long been used as antineoplastic medicine
in China. In recent years, with improvement in prepa-
ration, many TCMIs have been developed and used to
treat PLC, especially in patients with medium- or ad-
vanced-stage PLC. With advantages such as less toxici-
ty, being more economical and multifunctional in regu-
lating immunological function, as well as killing cancer
cells, TCMIs have been widely used clinically in Chi-
na. Besides PLC, TCMIs are indicated for various oth-
er malignant tumors, and their effects have been gradu-
ally testified by clinical trials. For example, Astragalus
injection has been used to treat cervical cancer;4 Oleum
Fructus Bruceae, Shengmai or Shenfu injection to treat
non-small cell lung cancer;56-58 and Cinobufacini or Be-
ta-elemene injection to treat progressive gastric cancer,
59 Many studies have shown that TCMIs had signifi-
cant effects on reducing cancer-related fatigue and
pain, alleviating respiratory tract infections and gastro-
intestinal symptoms, including diarrhea, nausea, and
vomiting, protecting liver function, and even ameliorat-
ing the symptoms of cachexia.60
However, in our review of the literature, we also found
some problems with TCMIs that need to be resolved
urgently. First, TCMIs are extracted from herbs, and al-
though they have been widely used clinically, their ma-
jor pharmacological active ingredients mostly remain
unknown. Second, the side effects, contraindications
and corresponding clinical data of TCMIs are rarely
specified in the product instructions. Third, improve-
ment in the preparation technology still cannot keep
down the frequent occurrence of allergy and phlebitis.
Fourth, clinical trials on TCMIs are abundant, and
they do testify to the effects of TCMIs on PLC from
different aspects. Unfortunately, none of them were
large multicenter trials with strict criteria. Instead,
most of the studies were not done under standard crite-
ria, so it is difficult to draw persuasive conclusions
about the effects of TCMIs for treating cancer when
conducting a meta-analysis.61,62 Finally, but not the
least, most of the clinical trials were conducted in Chi-
na, and the pharmacological activities of TCMIs have
not been tested in other areas and on other races. All
the problems discussed above have greatly obstructed
further application of TCMIs. Therefore, we call for
large-scale high-quality trials, intensive basic research
on and improvement of preparation of TCMIs, and
more advocates to tap the potential of TCMIs.
In clinical practice, combination of TCMIs with sur-
gery, TACE, percutaneous ethanol injection (PEI), ra-
diotherapy or chemotherapy protect hepatic function,
improve the immune system, increase sensitivity to
chemo- and radiotherapy, reduce side effects and com-
plications during chemo- and radiotherapy, improve
QOL, increase CR, PR and SD rates and KPS scores,
and prolong survival time. Even if TCMIs are taken
solely as palliative treatment, they could alleviate pa-
tients’symptoms.
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